PreveCeutical Medical Inc.

PreveCeutical Medical Inc. is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products.

Recent News

  • PreveCeutical Announces Appointment of Director and Public Officer

    Vancouver, British Columbia--(Newsfile Corp. - July 30, 2020) -  PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce the appointment of Edward James Henderson as the Public Officer and Director of its subsidiary company, PreveCeutical (Australia) Pty Ltd. (the "Subsidiary") effective immediately.Mr....

    2020-07-30 7:00 AM ET
  • PreveCeutical Approaches Completion of Non-Addictive Analgesic Program

    Vancouver, British Columbia--(Newsfile Corp. - July 21, 2020) -  PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that the current stage of the research of its disulfide linker technology in engineering analgesic peptides derived from endogenous pharmacology program ("Analgesic Program") is soon to...

    2020-07-21 7:00 AM ET
  • PreveCeutical Announces Advance in the Formulation and Biological Delivery of Therapy for Diabetes and Obesity

    Vancouver, British Columbia--(Newsfile Corp. - July 15, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical"), is pleased to announce that it has successfully demonstrated that delivery efficiency can be tailored based on vector composition in its Dual Gene Therapy Research Program.This update of PreveCeutical's...

    2020-07-15 7:00 AM ET
  • PreveCeutical Confirms Receipt of CBD For Sol-Gel

    Vancouver, British Columbia--(Newsfile Corp. - July 13, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical") is pleased to inform that the cannabis product required for its cannabinoid Sol-Gel program to address the COVID-19 pandemic (the "COVID-19 Sol-gel") (News Release dated May 4, 2020), was received by...

    2020-07-13 7:00 AM ET
  • PreveCeutical Announces Filing of Provisional Patent Application

    Vancouver, British Columbia--(Newsfile Corp. - July 8, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce it has filed a provisional application at the Australian Patent Office on July 1, 2020, entitled "Peptides and Uses Thereof", application number 2020902233, with the aim...

    2020-07-08 7:00 AM ET
  • PreveCeutical Announces Stability Data from CBD Sol-gel Product Development Program

    Vancouver, British Columbia--(Newsfile Corp. - July 6, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical"), is pleased to announce successful results from its Cannabinoid sol-gel product development program.We have successfully conducted a three-month physico-chemical stability test on cannabinoid sol-gel formulations designed for nose-to-brain ("NTB") delivery.The...

    2020-07-06 7:00 AM ET
  • PreveCeutical Announces Promising 3D Liver Tissue Testing of Potential Therapy for Diabetes and Obesity

    Vancouver, British Columbia--(Newsfile Corp. - June 29, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical"), is pleased to announce that it has successfully designed, screened and shortlisted a panel of smart-siRNA constructs with potent gene silencing activity (in vitro) in its Dual Gene Therapy Research Program.This further...

    2020-06-29 7:00 AM ET
  • PreveCeutical Executes Agreement for Development of CBD Sol-Gel Nasal Spray Formulation as a Potential Treatment for SARS-CoV-2 Infection

    Vancouver, British Columbia--(Newsfile Corp. - June 22, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical"), is pleased to announce that on June 18th, 2020, it has contracted UniQuest Pty Ltd. ("UniQuest") to apply the cannabinoid sol-gel ("CBD Sol-Gel") technology to develop a nasal spray formulation as a...

    2020-06-22 12:23 PM ET